Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry
Launched by WEST VIRGINIA UNIVERSITY · Oct 19, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how much oxygen is present in skin tumors, including those from skin cancer and melanoma, using a special technique called Electron Paramagnetic Resonance (EPR) Oximetry. The goal is to see how treatments, like oxygen therapy and standard cancer treatments, affect the oxygen levels in these tumors. By measuring this, researchers hope to understand more about how to improve cancer care for patients with skin tumors.
To be eligible for this study, participants should have a confirmed skin cancer diagnosis with a tumor that is at least 6 mm wide. Women who can become pregnant must have a negative pregnancy test before joining the trial. However, people with certain medical devices, allergies to specific products used in the study, or those who are pregnant or breastfeeding cannot participate. If you take part in this trial, you will help researchers gather important information that could lead to better treatments for skin cancer in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pathology-proven (histology or cytology) malignancy of any histology and site of origin
- • Visible tumor (primary or metastasis) involving the skin of at least 6 mm in diameter
- • Negative serum or urine pregnancy test within 72 hours prior to registration for women of childbearing potential
- Exclusion Criteria:
- • Implanted electric, magnetic or mechanically activated devices like a pacemaker, defibrillator, nerve stimulator, cochlear implant or portable infusion pump. Also individuals who have any non-MRI compatible implants
- • Individuals who have a ferromagnetic foreign body located in their body
- • Prior adverse reaction to a charcoal product (e.g., a local hypersensitive response from a black tattoo or from ingestion of activated charcoal)
- • Prior adverse reaction to gum Arabic, which is an ingredient in the India ink
- • Prior allergic reaction to medical adhesives
- • Psychiatric illness/social situations that would limit compliance with study requirements
- • Pregnant or lactating women. There is no known harm to the woman or her fetus from participating; this is precautionary only
About West Virginia University
West Virginia University (WVU) is a leading research institution dedicated to advancing healthcare through innovative clinical trials and research initiatives. With a strong commitment to improving patient outcomes, WVU harnesses its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies across a wide range of medical fields. The university collaborates with healthcare providers, industry partners, and regulatory bodies to ensure the highest standards of ethics and scientific integrity in its research endeavors. WVU strives to translate scientific discoveries into practical applications, ultimately enhancing the quality of care for diverse populations in West Virginia and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Morgantown, West Virginia, United States
Morgantown, West Virginia, United States
Patients applied
Trial Officials
Todd Tenenholz, MD
Principal Investigator
West Virginia University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials